Apremilast

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1428 publications

Pharmacokinetic and bioequivalence study of apremilast tablets in healthy Chinese subjects under fasting and fed conditions.

Pharmacokinetic and bioequivalence study of apremilast tablets in healthy Chinese subjects under fasting and fed conditions.

Journal: International journal of clinical pharmacology and therapeutics

Published: June 15, 2026

Apremilast combined with low-dose corticosteroids for lichenoid drug eruption following programmed cell death protein 1 inhibitor and lenvatinib therapy: A case report.

Apremilast combined with low-dose corticosteroids for lichenoid drug eruption following programmed cell death protein 1 inhibitor and lenvatinib therapy: A case report.

Journal: JAAD case reports

Published: May 22, 2026

Glycolic acid-integrated nanostructured lipid carriers of apremilast and quercetin co-delivery for the management of psoriasis.

Glycolic acid-integrated nanostructured lipid carriers of apremilast and quercetin co-delivery for the management of psoriasis.

Journal: Therapeutic delivery

Published: April 28, 2026

Apremilast for Acrodermatitis Continua of Hallopeau: Report of Two Cases and Review of the Literature.

Apremilast for Acrodermatitis Continua of Hallopeau: Report of Two Cases and Review of the Literature.

Journal: The Journal of dermatology

Published: April 20, 2026

Biological Therapy Leads to a Reduction in Systemic Inflammation but Leaves Serum Uric Acid Unmodified in Moderate-to-Severe Plaque Psoriasis: A Prospective Longitudinal Cohort Study.

Biological Therapy Leads to a Reduction in Systemic Inflammation but Leaves Serum Uric Acid Unmodified in Moderate-to-Severe Plaque Psoriasis: A Prospective Longitudinal Cohort Study.

Journal: Journal of clinical medicine

Published: April 10, 2026

DMARDs and gout therapy in patients with chronic arthritis and end-stage renal disease: a descriptive guide.

DMARDs and gout therapy in patients with chronic arthritis and end-stage renal disease: a descriptive guide.

Journal: Acta clinica Belgica

Published: April 05, 2026

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

Journal: Expert opinion on pharmacotherapy

Published: March 14, 2026

Immune cell-targeted nanocarrier delivery systems for inflammatory bowel disease therapy: mechanisms and strategies.

Immune cell-targeted nanocarrier delivery systems for inflammatory bowel disease therapy: mechanisms and strategies.

Journal: International journal of pharmaceutics

Published: March 11, 2026

Apremilast as an Adjuvant in Refractory Reactive Arthritis: A Retrospective Observational Study.

Apremilast as an Adjuvant in Refractory Reactive Arthritis: A Retrospective Observational Study.

Journal: Cureus

Published: March 09, 2026

Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potential.

Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potential.

Journal: European journal of medicinal chemistry

Published: March 02, 2026

Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling.

Mechanistic enhancement of oral bioavailability through a coamorphous apremilast-aceclofenac systems: integrated LC-MS/MS Bioanalysis, in vivo pharmacokinetics, and PBPK modeling.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: February 28, 2026

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.

Journal: The Journal of dermatological treatment

Published: February 24, 2026

Showing 1-12 of 1,428

Last Updated: 06/30/2026